검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-14 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Sarilumab |
Overview Company | Wei-Che Ko |
Overview Modality | ANTIBODY |
Overview Target | Melanoma |
Overview Indication | Skin Inflammation; Allergic Contact Dermatitis |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
MoA Mechanism | s and infections appeared limited |
MoA Biomarker | biomarker, imaging, or patient reported outcomes were included |
PK/PD Half-life | 10 h |
PK/PD Species | Human |
PK/PD Animal (cat.) | Human |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Human |
Toxicology Animal (cat.) | Human |
Toxicology Major finding | Comparative effectiveness and safety of sarilumab vs JAK inhibitors in late- and younger-onset rheumatoid arthritis.. Glucocorticoid (GC)- and MTX-sparing strategies are clinically important in RA, yet comparative real-world evidence for sarilumab (SAR) vs Janus kinase inhibitors (JAKi) is limited. Whether treatment effects differ by age at onset-late-onset RA (LORA) vs young-onset RA (YORA)-also … |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 3.5% |
Clinical ORR | 3.5% |
Clinical Result source | ClinicalTrials.gov NCT01900431 |
Clinical Data Tier / Score | A · 41 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-14 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Sarilumab |
Overview Company | Wei-Che Ko |
Overview Modality | ANTIBODY |
Overview Target | Melanoma |
Overview Indication | Skin Inflammation; Allergic Contact Dermatitis |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
MoA Mechanism | s and infections appeared limited |
MoA Biomarker | biomarker, imaging, or patient reported outcomes were included |
PK/PD Half-life | 10 h |
PK/PD Species | Human |
PK/PD Animal (cat.) | Human |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Human |
Toxicology Animal (cat.) | Human |
Toxicology Major finding | Comparative effectiveness and safety of sarilumab vs JAK inhibitors in late- and younger-onset rheumatoid arthritis.. Glucocorticoid (GC)- and MTX-sparing strategies are clinically important in RA, yet comparative real-world evidence for sarilumab (SAR) vs Janus kinase inhibitors (JAKi) is limited. Whether treatment effects differ by age at onset-late-onset RA (LORA) vs young-onset RA (YORA)-also … |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 3.5% |
Clinical ORR | 3.5% |
Clinical Result source | ClinicalTrials.gov NCT01900431 |
Clinical Data Tier / Score | A · 41 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) |
추천 비교
추천 비교